文献速递脑血管病

房颤患者口服抗凝治疗下仍发生缺血性卒中:复发风险与抗凝策略分析

Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation.
PubMed 文献 · Ann Neurol · 2020-02-27

该研究汇总7项前瞻性队列研究的个体患者数据,比较房颤患者中既往口服抗凝(OACprior)与未抗凝(OACnaive)者发生缺血性卒中后的复发风险。共纳入5413例患者,随访6128患者年,289例发生急性缺血性卒中(4.7%/年,95%CI 4.2-5.3%)。OACprior与复发急性缺血性卒中风险增加相关(HR=1.6,95%CI 1.2-2.3,p=0.005);改变抗凝类型(OACchanged)较继续原抗凝(OACunchanged)未降低复发风险(HR=1.2,95%CI 0.7-2.1,p=0.415)。

要点

  • 房颤患者既往口服抗凝仍发生缺血性卒中者,复发风险显著增加(HR=1.6)。
  • 改变抗凝药物类型未显著降低复发缺血性卒中风险(HR=1.2)。
  • 该高危人群需更好的二级预防策略。

核心结论

  • 房颤患者既往口服抗凝治疗仍发生缺血性卒中者,尽管CHA2DS2-Vasc评分与未抗凝者相似,复发缺血性卒中风险更高。

研究设计与样本

  • 研究为7项前瞻性队列研究的个体患者数据汇总分析,纳入房颤且近期脑缺血患者,比较OACprior(n=1195)与OACnaive(n=4119),并比较OACchanged(n=307)与OACunchanged(n=585)。
  • 共纳入5413例患者,中位年龄78岁(IQR 71-84),5136例(96.7%)以缺血性卒中为索引事件,入院中位NIHSS评分6分(IQR 2-12),中位CHA2DS2-Vasc评分5分(IQR 4-6)。

主要发现

  • 随访6128患者年期间,289例发生急性缺血性卒中,年发生率为4.7%(95%CI 4.2-5.3%)。
  • OACprior与急性缺血性卒中风险增加相关(HR=1.6,95%CI 1.2-2.3,p=0.005)。
  • OACchanged与OACunchanged相比,急性缺血性卒中风险无显著降低(HR=1.2,95%CI 0.7-2.1,p=0.415)。

关键数值与推荐

  • OACprior组与OACnaive组的CHA2DS2-Vasc评分相似(p=0.103)。
  • 复发急性缺血性卒中的年发生率为4.7%(95%CI 4.2-5.3%)。

临床怎么用

  • 对于既往口服抗凝仍发生缺血性卒中的房颤患者,应认识到其复发风险较高,需加强二级预防管理。
  • 改变抗凝药物类型(如VKA与DOAC互换或DOAC间转换)未显示降低复发风险,临床决策需个体化。

局限性

  • 研究为汇总分析,可能存在未测量的混杂因素。
  • OACchanged与OACunchanged的比较样本量较小(分别为307例和585例),统计效能有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: It is not known whether patients with atrial fibrillation (AF) with ischemic stroke despite oral anticoagulant therapy are at increased risk for further recurrent strokes or how ongoing secondary prevention should be managed. METHODS: We conducted an individual patient data pooled analysis of 7 prospective cohort studies that recruited patients with AF and recent cerebral ischemia. We compared patients taking oral anticoagulants (vitamin K antagonists [VKA] or direct oral anticoagulants [DOAC]) prior to index event (OACprior) with those without prior oral anticoagulation (OACnaive). We further compared those who changed the type (ie, from VKA or DOAC, vice versa, or DOAC to DOAC) of anticoagulation (OACchanged) with those who continued the same anticoagulation as secondary prevention (OACunchanged). Time to recurrent acute ischemic stroke (AIS) was analyzed using multivariate competing risk Fine-Gray models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS: We included 5,413 patients (median age = 78 years [interquartile range (IQR) = 71-84 years]; 5,136 [96.7%] had ischemic stroke as the index event, median National Institutes of Health Stroke Scale on admission = 6 [IQR = 2-12]). The median CHA2DS2-Vasc score (congestive heart failure, hypertension, age≥ 75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65-74 years, sex category) was 5 (IQR = 4-6) and was similar for OACprior (n = 1,195) and OACnaive (n = 4,119, p = 0.103). During 6,128 patient-years of follow-up, 289 patients had AIS (4.7% per year, 95% CI = 4.2-5.3%). OACprior was associated with an increased risk of AIS (HR = 1.6, 95% CI = 1.2-2.3, p = 0.005). OACchanged (n = 307) was not associated with decreased risk of AIS (HR = 1.2, 95% CI = 0.7-2.1, p = 0.415) compared with OACunchanged (n = 585). INTERPRETATION: Patients with AF who have an ischemic stroke despite previous oral anticoagulation are at a higher risk for recurrent ischemic stroke despite a CHA2DS2-Vasc score similar to those without prior oral anticoagulation. Better prevention strategies are needed for this high-risk patient group. ANN NEUROL 2020;87:677-687.

来源:Ann Neurol,查看原文。版权归原作者所有。

引用

  1. Seiffge DJ, De Marchis GM, Koga M, et al. Ischemic Stroke despite Oral Anticoagulant Therapy in Patients with Atrial Fibrillation. Ann Neurol. 2020. PMID: 32052481. doi:10.1002/ana.25700

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。